1964506-28-2

1964506-28-2 structure

Name: ODN 21595
Chemical Name: ODN 21595
CAS Number: 1964506-28-2
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways Immunology/Inflammation Toll-like Receptor (TLR)
Create Date: 2022-09-11 10:03:31
Modify Date: 2024-04-06 13:27:24
ODN 21595 is a Guanine-Modified TLR7 and TLR9 inhibitor. ODN 21595 inhibits the release of IFN-α and IL-6 with no cytotoxic. ODN 21595 reduces the expression of CD86 and HLA-DR. ODN 21595 has the potential for the research of systemic lupus erythematosus (SLE)[1].

Name	ODN 21595

Description	ODN 21595 is a Guanine-Modified TLR7 and TLR9 inhibitor. ODN 21595 inhibits the release of IFN-α and IL-6 with no cytotoxic. ODN 21595 reduces the expression of CD86 and HLA-DR. ODN 21595 has the potential for the research of systemic lupus erythematosus (SLE)[1].
Related Catalog	Signaling Pathways >> Immunology/Inflammation >> Toll-like Receptor (TLR) Research Areas >> Inflammation/Immunology
In Vitro	ODN 21595 (0.01, 0.1, 1, 10 μM; 24 h) inhibits the release of IFN-α in CpG-ODN 2216 (3 μM) and TLR7-ligand RNA-ORN 22075 (5 μM) stimulated human PBMCs[1]. ODN 21595 (0.01, 0.1, 1, 10 μM; 48 h) inhibits the secretion of IL-6 in CpG-ODN 2006 (100 nM) and imiquimod (5 μg/ml) stimulated human PBMCs[1]. ODN 21595 (0.1, 1, 10 μM; 24 h) inhibits the secretion of IL-6 in CpG-ODN 2006 (100 nM) and imiquimod (5 μg/ml) stimulated human B-cells[1]. ODN 21595 (1, 10 μM; 48 h) displays a lower stimulatory activity and reduces significantly the CpG-ODN 2006 (100 nM) or imiquimod (5 μg/ml)-induced expression of CD86 or HLA-DR in CD20+ B-cells[1]. Cell Cytotoxicity Assay[1] Cell Line: human PBMCs Concentration: 0.01, 0.1, 1, 10 μM Incubation Time: 48 h Result: Showed no cytotoxic for human PBMCs.
References	[1]. Römmler F, et al. Guanine-modified inhibitory oligonucleotides efficiently impair TLR7- and TLR9-mediated immune responses of human immune cells. PLoS One. 2015 Feb 19;10(2):e0116703.

No Any Chemical & Physical Properties